Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross―talk in the bone marrow of multiple myeloma patientsBASILE, Antonio; MOSCHETTA, Michele; SPECCHIA, Giorgina et al.Journal of pathology (Print). 2013, Vol 229, Num 1, pp 87-98, issn 0022-3417, 12 p.Article

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaCAVO, Michele; PANTANI, Lucia; NOZZOLI, Chiara et al.Blood. 2012, Vol 120, Num 1, pp 9-19, issn 0006-4971, 11 p.Article

Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemiasDI TUCCI, Anna Angela; MATTA, Gildo; DEPLANO, Simona et al.Haematologica (Roma). 2008, Vol 93, Num 9, pp 1385-1388, issn 0390-6078, 4 p.Article

HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic TargetRIA, Roberto; CATACCHIO, Ivana; ANNESE, Tiziana et al.Clinical cancer research (Print). 2014, Vol 20, Num 4, pp 847-858, issn 1078-0432, 12 p.Article

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma : updated results of a randomized controlled trial. CommentaryDURIE, Brian G. M; PALUMBO, Antonio; ZAMBELLO, Renato et al.Blood. 2008, Vol 112, Num 8, issn 0006-4971, 2998-2999, 3107-3114 [10 p.]Article